CKD 516

Drug Profile

CKD 516

Alternative Names: CKD-516; NOV-120401

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Chong Kun Dang
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Injection)
  • 01 Dec 2014 Phase-I clinical trials in Solid tumours in South Korea (PO) (NCT02300467)
  • 30 Jun 2012 Chong Kun Dang initiates enrolment in a phase I trial for Solid tumours in South Korea (NCT01560325)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top